Our team

Professor Goldstein is a conjoint clinical professor. He has been involved in a variety of clinical research projects ranging from laboratory basic science to novel therapeutics trials to psychosocial aspects of Cancer care. He has been PI of a number of NHMRC and Cancer Australia funded therapeutic trials including both investigator initiated and as Australian PI for multinational studies. He has also been involved with psychosocial and cross cultural/CALD research for many years. His clinical interests are treatment of GI malignancies including pancreas cancer, colorectal cancer, anal carcinoma, hepatobilary and upper GI malignancy and renal cell carcinoma and lymphoma. He has been a Chief or Principal Investigator on $31,000,000 peer reviewed funded grants and has over 430 peer reviewed publications.

His activity over many years in one of the least common cancers and least studied, until recently, in the GI area – pancreas cancer, as well as GIST and biliary cancers gives him great insight into the challenges of approaching a suite of rare cancers. He has also been involved in several large scale epidemiologic studies, the most recent looking at pancreatic cancer. He has contributed to pivotal data resulting in PBS changes in approval for adjuvant gemcitabine in pancreas cancer, imatinib in metastatic and adjuvant GIST and first line nab-paclitaxel in pancreatic cancer. He is part of the executive of the ARC portal program.

Professor Goldstein was the Director of the UNSW Translational Cancer Research Network, a $6,000,000 CINSW funded program. He is involved with research into  survivorship issues., in particular he was the Chief Investigator of a Cancer Institute NSW translational program grant of $3,100,000 to study the impact of chemotherapy induced peripheral neuropathy.

Professor Goldstein also actively participates in three laboratory research programs dealing with stromal biology, pancreas drug resistance and modelling optimal targeted therapies in sarcoma. He is currently the CI and facilitator of a CINSW pancreas cancer translational research program. He is also a CI of the UNSW precision medicine implementation research program led by Prof Natalie Taylor.

Professor Goldstein has also been a member of the Australian Gastro-Intestinal Trials Group Scientific Advisory Committee, was a board member and treasurer of the Gastro-Intestinal Cancer Institute for nine years, the longest serving president of the Clinical Oncology Society of Australia (COSA) and a member of both the American Society of Clinical Oncology (ASCO) and the American Association of Cancer Research. He serves on ASCO international committees engaged in supporting enhanced cancer service delivery in less developed countries.